2017
The effect of substance use disorders on the association between guideline-concordant long-term opioid therapy and all-cause mortality
Gaither J, Goulet J, Becker W, Crystal S, Edelman E, Gordon K, Kerns R, Rimland D, Skanderson M, Justice A, Fiellin D. The effect of substance use disorders on the association between guideline-concordant long-term opioid therapy and all-cause mortality. Drug And Alcohol Dependence 2017, 171: e68. DOI: 10.1016/j.drugalcdep.2016.08.196.Peer-Reviewed Original Research
2023
Perspectives on contingency management for alcohol use and alcohol‐associated conditions among people in care with HIV
Cohen S, DePhilippis D, Deng Y, Dziura J, Ferguson T, Fucito L, Justice A, Maisto S, Marconi V, Molina P, Paris M, Rodriguez‐Barradas M, Simberkoff M, Petry N, Fiellin D, Edelman E. Perspectives on contingency management for alcohol use and alcohol‐associated conditions among people in care with HIV. Alcohol Clinical And Experimental Research 2023, 47: 1783-1797. PMID: 37524371, PMCID: PMC10828101, DOI: 10.1111/acer.15159.Peer-Reviewed Original ResearchUnhealthy alcohol useAlcohol useContingency managementPrimary care settingSubset of participantsReward structureEvidence-based approachHIV clinicImplementation science frameworkTreatment trialsClinical trialsIntervention feasibilityCare settingsPromoting ActionAlcohol consumptionRelated conditionsBiochemical testingClinical contextHIVReward schedulePatientsReward processesInterventionTrialsBehavior changeConverging Evidence from Rodent and Human Studies on the Role of Spironolactone as a Potential Pharmacotherapy for Alcohol Use Disorder
Farokhnia M, Rentsch C, Chuong V, McGinn M, Elvig S, Douglass E, Gonzalez L, Sanfilippo J, Marchette R, Tunstall B, Fiellin D, Koob G, Justice A, Leggio L, Vendruscolo L. Converging Evidence from Rodent and Human Studies on the Role of Spironolactone as a Potential Pharmacotherapy for Alcohol Use Disorder. Alcohol 2023, 109: 83-84. DOI: 10.1016/j.alcohol.2023.03.071.Peer-Reviewed Original Research
2019
Integrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial
Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Deng Y, Fiellin LE, O'Connor PG, Bedimo R, Gibert CL, Marconi VC, Rimland D, Rodriguez-Barradas MC, Simberkoff MS, Tate JP, Justice AC, Bryant KJ, Fiellin DA. Integrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial. The Lancet HIV 2019, 6: e509-e517. PMID: 31109915, PMCID: PMC7161741, DOI: 10.1016/s2352-3018(19)30076-1.Peer-Reviewed Original ResearchConceptsAlcohol use disorderWeek 24Use disordersAlcohol treatmentAdverse eventsNumber of drinksTreatment medicationsPhysician managementAlcohol abuseMental Disorders-IV criteriaAlcohol-related careFormal alcohol treatmentKey exclusion criteriaTimeline followback methodMotivational enhancement therapyTreat populationHIV clinicHIV outcomesPrimary outcomeSpecialty referralsMean ageUS National InstitutesWeek 4Medical conditionsExclusion criteriaAssociation of Prescribed Opioids With Increased Risk of Community-Acquired Pneumonia Among Patients With and Without HIV
Edelman EJ, Gordon KS, Crothers K, Akgün K, Bryant KJ, Becker WC, Gaither JR, Gibert CL, Gordon AJ, Marshall BDL, Rodriguez-Barradas MC, Samet JH, Justice AC, Tate JP, Fiellin DA. Association of Prescribed Opioids With Increased Risk of Community-Acquired Pneumonia Among Patients With and Without HIV. JAMA Internal Medicine 2019, 179: 297-304. PMID: 30615036, PMCID: PMC6439696, DOI: 10.1001/jamainternmed.2018.6101.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyCommunity-acquired pneumoniaImmunosuppressive propertiesPrescribed opioidsCaP riskHIV statusMedian morphine equivalent daily doseVeterans Health Administration medical centersMorphine equivalent daily doseEquivalent daily doseAging Cohort StudyCase-control studyImmune-related outcomesRace/ethnicityIndex dateOpioid exposureCohort studyDaily doseOpioid propertiesStratified analysisMedical CenterMAIN OUTCOMEOpioidsMedicaid dataHIV
2016
The impact of prescribed opioids on CD4 cell count recovery among HIV‐infected patients newly initiating antiretroviral therapy
Edelman E, Gordon K, Tate J, Becker W, Bryant K, Crothers K, Gaither, Gibert C, Gordon A, Marshall B, Rodriguez‐Barradas M, Samet J, Skanderson M, Justice A, Fiellin D. The impact of prescribed opioids on CD4 cell count recovery among HIV‐infected patients newly initiating antiretroviral therapy. HIV Medicine 2016, 17: 728-739. PMID: 27186715, PMCID: PMC5053822, DOI: 10.1111/hiv.12377.Peer-Reviewed Original ResearchConceptsCD4 cell countBaseline CD4 cell countCell countPrescribed opioidsImmunosuppressive propertiesVeterans Aging Cohort Study (VACS) dataCD4 cell count recoveryAntiretroviral therapy responseCell count recoveryShort-term opioidsViral load suppressionCohort study dataOverall disease severityYear of initiationPrimary independent variableOpioid durationAntiretroviral therapyCount recoveryComorbid conditionsPharmacy dataOpioid propertiesTherapy responseOpioidsPatientsHIVHepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection
Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Re V, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas MC, Fiellin LE, Bryant K, Justice AC, Fiellin DA. Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. Journal Of Substance Use And Addiction Treatment 2016, 68: 62-67. PMID: 27431048, PMCID: PMC4976086, DOI: 10.1016/j.jsat.2016.06.002.Peer-Reviewed Original ResearchConceptsLiver enzyme elevationAlcohol use disorderUninfected patientsHepatotoxic medicationsHCV infectionUse disordersComposite endpointLiver injuryHIV/HCV co-infected patientsHCV co-infected patientsHIV/HCV statusPre-existing liver injuryCo-infected patientsCohort of HIVHepatitis C infectionHIV/HCVOpioid use disorderRisk of hepatotoxicityHCV statusHepatic safetyMedian ALTC infectionChart reviewEnzyme elevationHIV infection
2015
Receipt of opioid therapy guideline- concordant care among HIV+ and HIV− veterans
Gaither J, Edelman E, Becker W, Crystal S, Gordon K, Goulet J, Kerns R, Skanderson M, Weisberg D, Bryant K, Justice A, Fiellin D. Receipt of opioid therapy guideline- concordant care among HIV+ and HIV− veterans. Drug And Alcohol Dependence 2015, 146: e119. DOI: 10.1016/j.drugalcdep.2014.09.242.Peer-Reviewed Original Research
2014
Quality of HIV care and mortality in HIV-infected patients who use drugs and alcohol
Korthuis P, Kraemer K, McGinnis K, Skanderson M, Gordon A, Justice A, Fiellin D. Quality of HIV care and mortality in HIV-infected patients who use drugs and alcohol. Drug And Alcohol Dependence 2014, 140: e110. DOI: 10.1016/j.drugalcdep.2014.02.317.Peer-Reviewed Original Research
2011
Hepatic Safety and Antiretroviral Effectiveness in HIV‐Infected Patients Receiving Naltrexone
Tetrault JM, Tate JP, McGinnis KA, Goulet JL, Sullivan LE, Bryant K, Justice AC, Fiellin DA, Team F. Hepatic Safety and Antiretroviral Effectiveness in HIV‐Infected Patients Receiving Naltrexone. Alcohol Clinical And Experimental Research 2011, 36: 318-324. PMID: 21797892, PMCID: PMC3221963, DOI: 10.1111/j.1530-0277.2011.01601.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlanine TransaminaseAlcoholismAntiretroviral Therapy, Highly ActiveAspartate AminotransferasesCD4 Lymphocyte CountChemical and Drug Induced Liver InjuryCohort StudiesDatabases, FactualDrug InteractionsDrug-Related Side Effects and Adverse ReactionsFemaleHIV InfectionsHumansLiverLiver Function TestsMaleMiddle AgedNaltrexoneNarcotic AntagonistsOpioid-Related DisordersRNA, ViralVeteransConceptsNaltrexone prescriptionAlanine aminotransferaseOpioid dependenceVeterans Aging Cohort Study Virtual CohortAspartate aminotransferaseImpact of naltrexoneSignificant alanine aminotransferaseLiver enzyme elevationMean CD4 countHIV-infected individualsAST changesHepatic safetyHIV biomarkersOral naltrexoneCD4 countHIV RNAMedian durationEnzyme elevationMedian ageAST levelsNaltrexone useHepatic enzymesAntiretroviral effectivenessHIVPatients
2010
Erratum to: Erectile Dysfunction Drug Receipt, Risky Sexual Behavior and Sexually Transmitted Diseases in HIV
Cook R, McGinnis K, Samet J, Fiellin D, Rodriguez-Barradas M, Kraemer K, Gibert C, Scott Braithwaite R, Goulet J, Mattocks K, Crystal S, Gordon A, Oursler K, Justice A. Erratum to: Erectile Dysfunction Drug Receipt, Risky Sexual Behavior and Sexually Transmitted Diseases in HIV. Journal Of General Internal Medicine 2010, 25: 1383-1383. PMCID: PMC2988141, DOI: 10.1007/s11606-010-1492-9.Commentaries, Editorials and Letters